Application of pyrroloquinoline quinone or salt thereof in preparation of medicines for preventing and treating benign prostatic hyperplasia, and pharmaceutical composition

A technology of pyrroloquinoline quinone and benign prostatic hyperplasia, which is applied in the field of medicine, can solve the problems of reduced curative effect, achieve good inhibitory effect, reduce the prostate index, and improve the effect of SOD activity

Active Publication Date: 2021-04-16
CHINA PHARM UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Drug therapy is often limited to α1 receptor blockers, 5α reductase inhibitors or a combination of both; and with the continuation of treatment and the course of the disease, the curative effect will gradually decrease
However, there is no report about the use of pyrroloquinoline quinone or its salts in the prevention or treatment of BPH

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pyrroloquinoline quinone or salt thereof in preparation of medicines for preventing and treating benign prostatic hyperplasia, and pharmaceutical composition
  • Application of pyrroloquinoline quinone or salt thereof in preparation of medicines for preventing and treating benign prostatic hyperplasia, and pharmaceutical composition
  • Application of pyrroloquinoline quinone or salt thereof in preparation of medicines for preventing and treating benign prostatic hyperplasia, and pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] Prevention and treatment of pyrroloquinoline quinone disodium salt on testosterone propionate-induced benign prostatic hyperplasia.

[0024] 1. Experimental materials

[0025] 1.1 Experimental animals

[0026] SPF-ICR mice (old group: 8 months old, body weight 40-57g; young group: 8 weeks old, body weight 30-40g) were provided by the Experimental Animal Center of Nantong University, certificate number: SCXK (Su) 2014-0001.

[0027] 1.2 Drugs and reagents

[0028] The positive drug finasteride (5mg / tablet, Hangzhou MSD Pharmaceutical Co., Ltd.), the dosage is 1.67mg / kg, which is 20 times of the clinical human dosage (5mg / 60kg).

[0029] Pyrroloquinoline quinone disodium salt (Sigma), the dosage is 10 mg / kg, 1 mg / kg.

[0030] Experimental feed: full price nutrient pellet feed (Nanjing Synergy Animal Feed Factory).

[0031] The superoxide dismutase (SOD) kit and malondialdehyde (MDA) kit (Nanjing Jiancheng Bioengineering Institute) were used for determination according...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of pyrroloquinoline quinone or salt thereof in preparation of medicines for preventing and treating benign prostatic hyperplasia, and a pharmaceutical composition. Pyrroloquinoline quinone or the salt thereof has a remarkable inhibiting effect on benign prostatic hyperplasia.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the use of pyrroloquinoline quinone or a salt thereof in the preparation of drugs for preventing and treating prostatic hyperplasia and a pharmaceutical composition. Background technique [0002] Benign prostatic hyperplasia (BPH) has become the most common progressive disease leading to voiding disorders in middle-aged and elderly men, most of which gradually manifest clinical symptoms after the age of 40, and the incidence rate of men over 45 years old is 42-90%. It increases year by year with age, and can be as high as 70-80% by the age of 80. The clinical manifestations of BPH are enlarged prostate volume and lower urinary tract symptoms, which seriously affect the quality of life and physical and mental health of middle-aged and elderly people. The effect of androgen and its downstream related cytokines is considered to be the main reason for disrupting the internal homeostasis of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4745A61P13/08
Inventor 王广基甄乐王健鲲
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap